Bausch and Lomb Newswire (Page 10)

Bausch and Lomb Newswire (Page 10)

Comprehensive Real-Time News Feed for Bausch and Lomb. (Page 10)

Results 181 - 200 of 859 in Bausch and Lomb

  1. Arthur Reeves Ratcliffe, MD 1931 ~ 2017Read the original story w/Photo

    Feb 28, 2017 | The Highline Times

    ... on September 4, 1931 in Seattle Washington. He graduated from Franklin High School in 1949 where he won the Bausch and Lomb science medal in 1948. He went on to attend the University of Washington where he belonged to the Delta Kappa Epsilon ...

    Comment?

  2. Can Valeant Hit $48 Per Share?Read the original story w/Photo

    Mar 7, 2017 | Seeking Alpha

    Hitting $48 per share will require perpetual operating margins of approximately 18% and perform at 4% year-over-year growth. Central argument : Valeant is a high-risk/high-reward investment that can offer several multiples of upside if things go right, but also has a non-negligible chance of insolvency if matters aren't handled effectively.

    Comment?

  3. FMI Features Diabetic Macular Edema Market to Register a Healthy CAGR ...Read the original story w/Photo

    Mar 6, 2017 | SBWire

    Macular edema is condition in diabetes patient's that results in a retinal thickening within 2 disc diameter of the center of the macula. This results from changes in retinal microvascular that compromise the blood retinal barrier and cause leakage of plasma in the surrounding retina causing retinal edema.

    Comment?

  4. Valeant's Debt Refinance: Road To Perdition Or Blue Skies Ahead?Read the original story w/Photo

    Mar 6, 2017 | Seeking Alpha

    We have been wrong about Valeant for months and almost all of our buys that we made between $50 and $15 would be underwater today. Valeant pays down $1.1 billion in debt and seeks to restructure other debt, so we take one more look at Valeant objectively.

    Comment?

  5. Valeant's Backup Plan: Sell Bausch & LombRead the original story w/Photo

    Mar 3, 2017 | Seeking Alpha

    I am long VRX. It has been a painful ride, but I continue to believe they will work through their challenges without any major asset sales or dilutive capital raises, and especially without bankruptcy.

    Comment?

  6. U.S. Med Device Firm Visioneering Technologies to List On ASXRead the original story

    Mar 1, 2017 | BioSpace

    Visioneering Technologies, Inc. , a US based medical device company, is pleased to announce the opening of its fully underwritten Initial Public Offering to raise A$33.3 million. The IPO proceeds will provide capital as VTI broadens its US launch of its NaturalVue Multifocal daily disposable contact lenses for adults with presbyopia and children with myopia .

    Comment?

  7. Bausch + Lomb And Nicox Resubmit US New Drug Application For Novel...Read the original story w/Photo

    Feb 26, 2017 | Drugs.com

    Valeant Pharmaceuticals International, Inc.'s wholly owned subsidiary, Bausch + Lomb, and Nicox S.A. today announced the resubmission of a New Drug Application to the U.S. Food and Drug Administration seeking approval for latanoprostene bunod ophthalmic solution, 0.024%. Latanoprostene bunod is an intraocular pressure lowering single-agent eye drop dosed once daily, for patients with open angle glaucoma or ocular hypertension .

    Comment?

  8. It's Time to Face the Facts: Valeant Pharmaceuticals Is in Deep TroubleRead the original story w/Photo

    Mar 1, 2017 | The Motley Fool

    As you might have imagined by the 14% decline in the company's share price yesterday, Valeant's report didn't sit well with Wall Street. For the quarter, the company reported $2.4 billion in sales, which works out to a year-over-year decline of 13%.

    Comment?

  9. Valeant Updates Status Of Bausch & Lomb Tampa PlantRead the original story

    Feb 28, 2017 | BioSpace

    Valeant Pharmaceuticals International Inc. says it has fixed the problems at a Bausch & Lomb manufacturing plant in Tampa that delayed work on a new drug for glaucoma. Valeant now hopes to get the drug on the market this year, Joseph Papa, chairman and CEO, said during a conference call with analysts early Tuesday.

    Comment?

  10. Intraocular Lens Market - Global Industry Analysis, Size, Share,...Read the original story w/Photo

    Feb 28, 2017 | PR Newswire

    Cataract is an eye disease characterized by cloudiness / opaqueness of the natural lens of the eye, which leads to diminished vision, and if not treated leads to permanent loss of vision. Intraocular Lens is a type of lens implanted in the eye, for the treatment of cataract.

    Comment?

  11. Valeant Pharmaceuticals shares fall as it lowers guidance for 2017Read the original story

    Feb 28, 2017 | Canadian Business Magazine

    Shares in Valeant Pharmaceuticals tumbled Tuesday after the drugmaker warned revenues and profits will drop more than analysts had anticipated for this year. The company's stock fell 9.5 per cent, losing $2.06 at $19.88 in midday trading on the Toronto Stock Exchange.

    Comment?

  12. Valeant shares tank despite better-than-expected 4Q results 0:0Read the original story

    Feb 28, 2017 | New York Post

    ... in a note Tuesday. Koffler noted that the company forecasted 2017 growth at its branded prescription and Bausch and Lomb segments despite negative to flat performance in 2016. Total revenue fell 13 percent from the year-ago quarter and the company ...

    Comment?

  13. Why Valeant Pharmaceuticals Is Tumbling TodayRead the original story w/Photo

    Feb 28, 2017 | The Motley Fool

    The drugmaker's fourth-quarter and full-year financials did little to restore confidence in investors that sales and profit will begin growing again anytime soon. Valeant Pharmaceuticals investors have been dealt a seemingly endless stream of disappointments since revelations emerged of improper marketing and pricing strategies in 2015.

    Comment?

  14. B&L parent posts loss in Q4Read the original story

    Feb 28, 2017 | Rochester Business Journal

    Bausch & Lomb Inc. parent Valeant Pharmaceuticals International Inc. Tuesday reported a net loss and a drop in year-over-year fourth-quarter sales. The Canadian business posted a net loss of $515 million, or $1.47 a share, compared with a net loss of $385 million, or $1.12 a share, during the prior year's quarter.

    Comment?

  15. Arthur Reeves Ratcliffe, MDRead the original story w/Photo

    Feb 28, 2017 | Highline Times

    ... on September 4, 1931 in Seattle Washington. He graduated from Franklin High School in 1949 where he won the Bausch and Lomb science medal in 1948. He went on to attend the University of Washington where he belonged to the Delta Kappa Epsilon ...

    Comment?

  16. Valeant Q4 loss grows, sales fall 13% but adjusted earnings above estimatesRead the original story w/Photo

    Feb 28, 2017 | 680News

    Valeant Pharmaceuticals International Inc says its fourth quarter loss grew to US$515 million as the drug company's revenue fell 13 per cent compared with the same period in 2015. The Montreal-area company's net loss, reported in U.S. currency, was equal to $1.47 per share while revenue was $2.4 billion, down $355 million from a year earlier.

    Comment?

  17. Valeant Plunges On 'Unrealistic' 2017 Guidance, Analyst SaysRead the original story w/Photo

    Feb 28, 2017 | Investor's Business Daily

    ... $8.9 billion. Valeant also guided to 2%-5% growth in its branded prescription unit and 5%-7% growth in its Bausch and Lomb segment. But in the fourth quarter, sales of branded scripts fell 17.2%, to $829 million, and the Bausch and Lomb business ...

    Comment?

  18. UPDATE 3-Valeant predicts tough 2017 with revenue to declineRead the original story w/Photo

    Feb 28, 2017 | Reuters

    The headquarters of Valeant Pharmaceuticals International Inc is seen in Laval, Quebec in this file picture taken November 9, 2015. ) on Tuesday said that 2017 would be another year of transition with revenues falling as much as 8 percent amid drug price pressure and fewer prescriptions.

    Comment?

  19. At the open: TSX rises as Bank of Montreal jumpsRead the original story w/Photo

    Feb 28, 2017 | The Globe and Mail

    ... reported a better-than-expected quarterly profit on Tuesday, helped by lower costs and strength in its Bausch and Lomb eyecare business, but its net loss widened and the company said it was feeling pricing pressure. U.S. stocks opened slightly lower ...

    Comment?

  20. Valeant Shares Plummet After Reporting 13% Drop In SalesRead the original story w/Photo

    Feb 28, 2017 | TheStreet.com

    Valeant shares were plummeting ahead of market's open Tuesday despite earnings that beat consensus estimates. The drop was due to declining sales and a long-term debt dogging the biotech company.

    Comment?